Quantcast

Sorrento to Present at BIO Business Forum

June 20, 2014

SAN DIEGO, June 20, 2014 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the BIO Business Forum, taking place June 23(rd)-26(th), 2014 in San Diego, CA. The presentation will take place in the Imperial Beach Presentation Room on Tuesday, June 24 at 2:45 pm PDT.

About Sorrento Therapeutics, Inc.
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset Cynviloq(TM), the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opioid TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat advanced cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody-drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, therapeutic mono- and bi-specific antibodies, and ADCs.

For More information, please visit www.sorrentotherapeutics.com.

SOURCE Sorrento Therapeutics, Inc.


Source: PR Newswire



comments powered by Disqus